The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...

– Interim results indicate cognitive improvement in the active treatment group compared to placebo ...

SINGAPORE I5, 2024 I SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for ...

SÖDERTÄLJE, Sweden I6, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the ...

SOUTH SAN FRANCISCO, CA, USA I6, 2024 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III ...

LYON, France I6, 2024 I MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...

WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...

BALDWIN PARK, CA, USA I2, 2024 I StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and ...

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S.